JP2019104705A - Fat metabolism improver, method for producing fat metabolism improver, and composition and molding - Google Patents
Fat metabolism improver, method for producing fat metabolism improver, and composition and molding Download PDFInfo
- Publication number
- JP2019104705A JP2019104705A JP2017238375A JP2017238375A JP2019104705A JP 2019104705 A JP2019104705 A JP 2019104705A JP 2017238375 A JP2017238375 A JP 2017238375A JP 2017238375 A JP2017238375 A JP 2017238375A JP 2019104705 A JP2019104705 A JP 2019104705A
- Authority
- JP
- Japan
- Prior art keywords
- fat metabolism
- improving agent
- extract
- metabolism improving
- rose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004060 metabolic process Effects 0.000 title claims abstract description 139
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 238000000465 moulding Methods 0.000 title abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 77
- 238000000605 extraction Methods 0.000 claims abstract description 65
- 229940029079 rose petal extract Drugs 0.000 claims abstract description 65
- 239000004480 active ingredient Substances 0.000 claims abstract description 44
- 239000000284 extract Substances 0.000 claims abstract description 34
- 239000002904 solvent Substances 0.000 claims abstract description 33
- 241000196324 Embryophyta Species 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 109
- 241000220317 Rosa Species 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 235000011449 Rosa Nutrition 0.000 abstract description 14
- 235000004789 Rosa xanthina Nutrition 0.000 abstract description 7
- 241000220222 Rosaceae Species 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 20
- 238000011282 treatment Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 239000000796 flavoring agent Substances 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- 150000004665 fatty acids Chemical class 0.000 description 14
- 235000019634 flavors Nutrition 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 102000007330 LDL Lipoproteins Human genes 0.000 description 12
- 108010007622 LDL Lipoproteins Proteins 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 239000012046 mixed solvent Substances 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 9
- 239000003599 detergent Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 101150058703 ACC1 gene Proteins 0.000 description 7
- 101150013552 LDLR gene Proteins 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000009194 climbing Effects 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000109329 Rosa xanthina Species 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 101150064015 FAS gene Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 235000016588 Rosa centifolia Nutrition 0.000 description 5
- 241000914160 Rosa x centifolia Species 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000004136 fatty acid synthesis Effects 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108010018763 Biotin carboxylase Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 229940051866 mouthwash Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 239000004129 EU approved improving agent Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000000520 Rosa foetida Nutrition 0.000 description 3
- 241001278881 Rosa foetida Species 0.000 description 3
- 244000181025 Rosa gallica Species 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001055 chewing effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- -1 pH adjusters Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000003021 water soluble solvent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZXFNOEJFYLQUSB-UHFFFAOYSA-N (2-methyl-4-phenylbutan-2-yl) acetate Chemical compound CC(=O)OC(C)(C)CCC1=CC=CC=C1 ZXFNOEJFYLQUSB-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 2
- 102100021641 Acetyl-CoA carboxylase 2 Human genes 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000004533 Hesperis matronalis Species 0.000 description 2
- 235000015847 Hesperis matronalis Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 235000000662 Rosa banksiae Nutrition 0.000 description 2
- 241001278830 Rosa banksiae Species 0.000 description 2
- 235000000539 Rosa canina Nutrition 0.000 description 2
- 240000008530 Rosa canina Species 0.000 description 2
- 235000000664 Rosa chinensis Nutrition 0.000 description 2
- 240000008254 Rosa chinensis Species 0.000 description 2
- 235000000533 Rosa gallica Nutrition 0.000 description 2
- 235000004815 Rosa hugonis Nutrition 0.000 description 2
- 241000109371 Rosa hugonis Species 0.000 description 2
- 235000000654 Rosa luciae Nutrition 0.000 description 2
- 244000018676 Rosa sp Species 0.000 description 2
- 241000806737 Rosa wichuraiana Species 0.000 description 2
- 235000005073 Rosa x alba Nutrition 0.000 description 2
- 241000109463 Rosa x alba Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010074438 Sterol Regulatory Element Binding Protein 2 Proteins 0.000 description 2
- 102000008079 Sterol Regulatory Element Binding Protein 2 Human genes 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000473679 Cyanocephalus rugosus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000005598 Helictotrichon sempervirens Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241001247496 Hoodia triebneri Species 0.000 description 1
- 244000271603 Hoya multiflora Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 241001537210 Perna Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 235000000647 Rosa californica Nutrition 0.000 description 1
- 241001278843 Rosa californica Species 0.000 description 1
- 235000010337 Rosa dumalis Nutrition 0.000 description 1
- 235000000103 Rosa fedtschenkoana Nutrition 0.000 description 1
- 241000593533 Rosa fedtschenkoana Species 0.000 description 1
- 241001225283 Rosa fujisanensis Species 0.000 description 1
- 235000010075 Rosa gigantea Nutrition 0.000 description 1
- 235000000523 Rosa glauca Nutrition 0.000 description 1
- 241001278847 Rosa glauca Species 0.000 description 1
- 235000000661 Rosa laevigata Nutrition 0.000 description 1
- 241001278833 Rosa laevigata Species 0.000 description 1
- 235000015027 Rosa luciae var fujisanensis Nutrition 0.000 description 1
- 240000003746 Rosa majalis Species 0.000 description 1
- 235000016555 Rosa majalis Nutrition 0.000 description 1
- 235000000657 Rosa moschata Nutrition 0.000 description 1
- 235000000656 Rosa multiflora Nutrition 0.000 description 1
- 244000050053 Rosa multiflora Species 0.000 description 1
- 235000004827 Rosa nitida Nutrition 0.000 description 1
- 241000109398 Rosa nitida Species 0.000 description 1
- 240000002289 Rosa odorata Species 0.000 description 1
- 235000004780 Rosa palustris Nutrition 0.000 description 1
- 241000109402 Rosa palustris Species 0.000 description 1
- 235000000518 Rosa pimpinellifolia Nutrition 0.000 description 1
- 235000004779 Rosa primula Nutrition 0.000 description 1
- 241000109415 Rosa primula Species 0.000 description 1
- 235000015054 Rosa roxburghii var hirtula Nutrition 0.000 description 1
- 240000004567 Rosa roxburghii var. hirtula Species 0.000 description 1
- 235000000659 Rosa rugosa Nutrition 0.000 description 1
- 240000006066 Rosa rugosa Species 0.000 description 1
- 235000009791 Rosa sp Nutrition 0.000 description 1
- 241001278863 Rosa spinosissima Species 0.000 description 1
- 235000000529 Rosa virginiana Nutrition 0.000 description 1
- 240000001152 Rosa virginiana Species 0.000 description 1
- 235000010295 Rosa x kordesii Nutrition 0.000 description 1
- 235000001659 Rosa x odorata nothovar gigantea Nutrition 0.000 description 1
- 241000698291 Rugosa Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、脂肪代謝改善剤、脂肪代謝改善剤の製造方法、組成物および成形体に関する。 The present invention relates to a fat metabolism improving agent, a method for producing a fat metabolism improving agent, a composition, and a molded article.
近年、日本等の先進諸国を始め、急速な近代化および欧米化が進展しているアジア諸国等では、食生活やライフスタイルの変化等に伴い、人口に占める肥満者の割合が増加し、これに起因する生活習慣病（糖尿病、高血圧、高脂血症等）の罹患者も増加している。このようなことから、肥満を改善することが重要である。 In recent years, in advanced Asian countries such as Japan and other Asian countries where rapid modernization and westernization are progressing, the ratio of obese people to the population increases with changes in diet and lifestyle, etc. The number of people suffering from lifestyle-related diseases (diabetes, high blood pressure, hyperlipidemia, etc.) is also increasing. For these reasons, it is important to improve obesity.
肥満を改善するためには、一般に、摂取エネルギーを制限することや、既に体内に蓄積している脂肪を低減させることが考えられる。肥満症の治療においては、摂取エネルギーを制限することを中心に考えられている。 In order to improve obesity, it is generally considered to limit energy intake or to reduce fat that has already accumulated in the body. In the treatment of obesity, it is mainly considered to limit the energy intake.
しかしながら、摂取エネルギーを制限することは、空腹感あるいはストレスといった肉体的および精神的苦痛を強いるものである。そのため、脂肪代謝を改善し、体内に蓄積している脂肪を低減させること（例えば、脂肪の分解を促進すること、または体脂肪の蓄積を抑制すること等）が注目されている。 However, limiting the energy intake imposes physical and mental distress such as hunger or stress. Therefore, attention is focused on improving fat metabolism and reducing fat accumulated in the body (for example, promoting degradation of fat or suppressing accumulation of body fat).
植物由来の成分は、種々の研究によって様々な生理機能性を有することが確認されており、また、一般に、副作用の可能性が小さいという点において、生理機能改善剤としての利用が期待されている。 Plant-derived components have been confirmed to have various physiological functions by various studies, and in general, they are expected to be used as physiological function improving agents in that the possibility of side effects is small. .
脂肪の分解を促進したり、体脂肪の蓄積を抑制したりする脂肪代謝改善剤においても、植物由来の成分として、藻類の抽出物（例えば、特許文献１参照）が提案されている。 Also in a fat metabolism improving agent that promotes the decomposition of fat or suppresses the accumulation of body fat, an algal extract (see, for example, Patent Document 1) is proposed as a plant-derived component.
しかしながら、従来の植物由来成分は、総合的脂肪代謝に対する幅広い機能性を有するという点において十分満足できるものではなく、細胞レベルで脂肪代謝を改善し、これらの性質を満足する脂肪代謝改善剤が切望されている。 However, conventional plant-derived components are not sufficiently satisfactory in that they have a wide range of functions for total fat metabolism, and improve fat metabolism at the cellular level, and fat metabolism improving agents satisfying these properties are in great need It is done.
本発明の目的は、細胞レベルでの総合的な脂肪代謝を効果的に改善する脂肪代謝改善剤を提供すること、当該脂肪代謝改善剤の製造方法を提供すること、また、当該脂肪代謝改善剤を含有する組成物、成形体を提供することにある。 An object of the present invention is to provide a fat metabolism improving agent that effectively improves the overall fat metabolism at the cellular level, to provide a method for producing the fat metabolism improving agent, and also to provide the fat metabolism improving agent. It is an object of the present invention to provide a composition containing the
このような目的は、下記（１）〜（９）に記載の本発明により達成される。
（１） バラ花弁抽出物を有効成分として含有することを特徴とする脂肪代謝改善剤。
Such an object is achieved by the present invention described in the following (1) to (9).
(1) A fat metabolism improving agent comprising a rose petal extract as an active ingredient.
（２） 前記バラ花弁抽出物は、バラ属に属する植物からの抽出物である上記（１）に記載の脂肪代謝改善剤。 (2) The agent for improving fat metabolism according to (1), wherein the rose petal extract is an extract from a plant belonging to the genus Ros.
（３） 前記バラ花弁抽出物は、エタノールを含有する抽出溶媒による抽出物である上記（１）または（２）に記載の脂肪代謝改善剤。 (3) The agent for improving fat metabolism according to (1) or (2) above, wherein the rose petal extract is an extract with an extraction solvent containing ethanol.
（４） エタノールを含有する抽出溶媒と、バラ花弁とを接触させて、前記バラ花弁の含有成分を抽出する抽出工程を有することを特徴とする脂肪代謝改善剤の製造方法。 (4) A method for producing a fat metabolism improving agent, which comprises an extraction step of bringing an extractant containing ethanol into contact with a rose petal to extract a component of the rose petal.
（５） 前記抽出工程において、前記バラ花弁を前記抽出溶媒中に浸漬する上記（４）に記載の脂肪代謝改善剤の製造方法。 (5) The method for producing a fat metabolism improving agent according to (4) above, wherein the rose petals are immersed in the extraction solvent in the extraction step.
（６） 前記抽出溶媒中における前記エタノールの含有率は、２体積％以上８０体積％以下である上記（４）または（５）に記載の脂肪代謝改善剤の製造方法。 (6) The method for producing a fat metabolism improving agent according to (4) or (5) above, wherein the content of ethanol in the extraction solvent is 2% by volume or more and 80% by volume or less.
（７） 前記抽出溶媒中における水の含有率は、２０体積％以上９５体積％以下である上記（４）ないし（６）のいずれかに記載の脂肪代謝改善剤の製造方法。 (7) The method for producing a fat metabolism improving agent according to any one of (4) to (6) above, wherein the water content in the extraction solvent is 20% by volume or more and 95% by volume or less.
（８） 上記（１）ないし（３）のいずれかに記載の脂肪代謝改善剤とその他の成分とを含有することを特徴とする組成物。 (8) A composition comprising the fat metabolism improving agent according to any one of the above (1) to (3) and other components.
（９） 上記（１）ないし（３）のいずれかに記載の脂肪代謝改善剤とその他の成分とを含有することを特徴とする成形体。 (9) A molded article comprising the fat metabolism improving agent according to any one of the above (1) to (3) and other components.
本発明によれば、細胞レベルでの総合的な脂肪代謝を効果的に改善する脂肪代謝改善剤を提供すること、当該脂肪代謝改善剤の製造方法を提供すること、また、当該脂肪代謝改善剤を含有する組成物、成形体を提供することができる。 According to the present invention, there is provided an agent for improving fat metabolism which effectively improves overall fat metabolism at cellular level, a method for producing the agent for improving fat metabolism, and the agent for improving fat metabolism. It is possible to provide a composition containing the
以下、本発明の好適な実施形態について詳細に説明する。
［脂肪代謝改善剤］
まず、本発明の脂肪代謝改善剤について説明する。
Hereinafter, preferred embodiments of the present invention will be described in detail.
[Fat metabolism improving agent]
First, the fat metabolism improving agent of the present invention will be described.
本発明の脂肪代謝改善剤は、バラ花弁抽出物を有効成分として含有することを特徴とする。 The fat metabolism improving agent of the present invention is characterized by containing a rose petal extract as an active ingredient.
本発明に係るバラ花弁抽出物は、動物に投与されたときに、脂肪代謝（特に肝臓（肝細胞）における脂肪代謝）に関連する遺伝子（脂肪代謝遺伝子）の発現を調節する作用を有する。具体的には、血漿中から肝細胞内へＬＤＬ（低比重リポタンパク質：Ｌｏｗ Ｄｅｎｓｉｔｙ Ｌｉｐｏｐｒｏｔｅｉｎ）の取り込みに関与する遺伝子の発現を促進することによって脂肪輸送を促進する。また、脂肪酸のβ酸化に関与する遺伝子の発現を促進することによって蓄積脂肪の分解を促進するとともに、脂肪酸の合成に関与する遺伝子の発現を抑制することにより脂肪の蓄積を抑制する。これらが相乗的に作用することにより、細胞レベルでの総合的な脂肪代謝がより効果的に改善される。 The rose petal extract according to the present invention has an action of regulating the expression of a gene (fat metabolism gene) related to fat metabolism (particularly, fat metabolism in liver (hepatocytes)) when administered to an animal. Specifically, it promotes fat transport by promoting the expression of genes involved in the uptake of LDL (Low Density Lipoprotein) from plasma into hepatocytes. Moreover, while promoting the degradation of accumulated fat by promoting the expression of a gene involved in β-oxidation of fatty acid, the accumulation of fat is suppressed by suppressing the expression of a gene involved in the synthesis of fatty acid. By acting synergistically, the overall fat metabolism at the cellular level is more effectively improved.
そして、本発明の脂肪代謝改善剤は、上記のような作用を有するバラ花弁抽出物を有効成分として含むことにより、従来の脂肪代謝改善剤とは異なり、細胞レベルで総合的に脂肪代謝を改善することができる。 And, the fat metabolism improving agent of the present invention improves the fat metabolism comprehensively at the cellular level unlike the conventional fat metabolism improving agents by containing the rose petal extract having the above-mentioned action as an active ingredient. can do.
したがって、本発明の脂肪代謝改善剤は、例えば、脂肪代謝促進（特に、肝臓の脂肪代謝促進）、体脂肪低減促進、脂肪肝の予防または治療、肥満の予防または治療、メタボリックシンドロームの予防または治療、肥満に起因する糖尿病、高血圧、高脂血症等の生活習慣病の予防または治療等のために用いることができる。 Therefore, the agent for improving fat metabolism according to the present invention is, for example, promoting fat metabolism (in particular, promoting fat metabolism in the liver), promoting body fat reduction, preventing or treating fatty liver, preventing or treating obesity, preventing or treating metabolic syndrome It can be used for the prevention or treatment of lifestyle-related diseases such as diabetes caused by obesity, hypertension, hyperlipidemia and the like.
本発明の脂肪代謝改善剤（後述する本発明の組成物、成形体も同様）は、動物としてのヒトに適用されるものであってもよいし、ヒト以外の動物に適用されるものであってもよい。 The fat metabolism improving agent of the present invention (the composition of the present invention to be described later and the molded body are the same) may be applied to humans as animals or may be applied to animals other than humans. May be
なお、本明細書において、脂肪代謝とは、血漿中から肝細胞内へＬＤＬを取り込む作用、肝細胞において脂肪酸をβ酸化により分解する作用、および、肝細胞における脂肪酸の合成を抑制する作用を含む概念である。 In the present specification, fat metabolism includes the action of taking LDL from plasma into hepatocytes, the action of degrading fatty acids by β-oxidation in hepatocytes, and the action of suppressing the synthesis of fatty acids in hepatocytes. It is a concept.
本発明の脂肪代謝改善剤によって発現が調整される脂肪代謝遺伝子としては、具体的には、以下のようなものが挙げらる。すなわち、脂肪輸送に関与する遺伝子としては、例えば、ＬＤＬ受容体（ＬＤＬＲ：Ｌｏｗ Ｄｅｎｓｉｔｙ Ｌｉｐｏｐｒｏｔｅｉｎ Ｒｅｃｅｐｔｏｒ）遺伝子等が挙げられる。また、脂肪酸のβ酸化に関与する遺伝子としては、例えば、ＣＰＴ１ａ（Ｃａｒｎｉｔｉｎｅ／Ｐａｌｍｉｔｏｙｌ−ｔｒａｎｓｆｅｒａｓｅ １ａ）遺伝子、ＡＣＯＸ（Ｐｅｒｏｘｉｓｏｍａｌ ａｓｙｌ−ＣｏＡ ｏｘｉｄｅ）遺伝子等が挙げられる。また、脂肪酸の合成に関与する遺伝子としては、例えば、ＡＣＣ１（Ａｃｅｔｙｌ ＣｏＡ Ｃａｒｂｏｘｙｌａｓｅ １）遺伝子、ＡＣＣ２（Ａｃｅｔｙｌ ＣｏＡ Ｃａｒｂｏｘｙｌａｓｅ ２）遺伝子、ＳＲＥＢＰ２（Ｓｔｅｒｏｌ Ｒｅｇｕｌａｔｏｒｙ Ｅｌｅｍｅｎｔ−Ｂｉｎｄｉｎｇ Ｐｒｏｔｅｉｎ ２）遺伝子、ＳＲＥＢＰ１ｃ（Ｓｔｅｒｏｌ Ｒｅｇｕｌａｔｏｒｙ Ｅｌｅｍｅｎｔ−Ｂｉｎｄｉｎｇ Ｐｒｏｔｅｉｎ １ｃ）遺伝子、ＦＡＳ（Ｆａｔｔｙ ａｃｉｄ ｓｙｎｔｈａｓｅ）遺伝子等が挙げられる。 Specific examples of fat metabolism genes whose expression is regulated by the fat metabolism improving agent of the present invention include the following. That is, as a gene involved in fat transport, for example, LDL receptor (LDLR: Low Density Lipoprotein Receptor) gene and the like can be mentioned. Further, as a gene involved in β-oxidation of fatty acid, for example, CPT1a (Carnitine / Palmitoyl-transferase 1a) gene, ACOX (Peroxosomal asyl-CoA oxide) gene and the like can be mentioned. Moreover, as a gene involved in fatty acid synthesis, for example, ACC1 (Acetyl CoA Carboxylase 1) gene, ACC2 (Acetyl CoA Carboxylase 2) gene, SREBP2 (Sterol Regulatory Element-Binding Protein 2) gene, SREBP1 c (Sterol Regulatory Element- Examples include Binding Protein 1c) gene, FAS (Fatty acid synthase) gene and the like.
本発明に係るバラ花弁抽出物と上記の遺伝子との関係の具体例は、以下のとおりである。 The specific example of the relationship between the rose petal extract and the above-mentioned gene according to the present invention is as follows.
すなわち、本発明に係るバラ花弁抽出物は、ＬＤＬＲ遺伝子の発現を促進する作用を有する。細胞内へのＬＤＬ受容体遺伝子の発現が促進されることによって、血漿中から細胞内への、ＬＤＬ（低比重リポタンパク質）の取り込み（脂肪輸送）が促進される、特に、肝臓に発現するＬＤＬＲ遺伝子は、血漿ＬＤＬの減少に大きな役割を果たしている。 That is, the rose petal extract according to the present invention has an action of promoting the expression of the LDLR gene. By promoting expression of the LDL receptor gene into cells, the uptake of LDL (low density lipoprotein) from plasma into cells is promoted (fat transport), in particular, LDLR expressed in the liver Genes play a major role in the reduction of plasma LDL.
また、本発明に係るバラ花弁抽出物は、ＣＰＴ１ａ遺伝子、ＡＣＯＸ遺伝子の発現を促進する作用を有する。これらの遺伝子の発現が促進されることによって、脂肪酸のβ酸化が促進され、蓄積脂肪の分解が促進される。 In addition, the rose petal extract according to the present invention has an action of promoting the expression of the CPT1a gene and the ACOX gene. By promoting the expression of these genes, β-oxidation of fatty acids is promoted and the degradation of accumulated fat is promoted.
さらに、本発明に係るバラ花弁抽出物は、ＡＣＣ１遺伝子、ＳＲＥＢＰ１ｃ遺伝子の発現を抑制する作用を有する。これらの遺伝子の発現が抑制されることによって、肝臓における脂肪酸の合成が抑制され、脂肪の蓄積が抑制される。 Furthermore, the rose petal extract according to the present invention has an action of suppressing the expression of the ACC1 gene and the SREBP1c gene. By suppressing the expression of these genes, synthesis of fatty acids in the liver is suppressed and accumulation of fat is suppressed.
また、本発明に係るバラ花弁抽出物（脂肪代謝改善剤）は、バラ特有の優れた香気を有している。特に、経口で摂取した場合にも、穏やかな香気を感じることができ、かつ、苦み、渋み、えぐみ等の不快な味覚は抑えられているため、全体として優れた風味が得られる。したがって、経口等の各種の方法での摂取において、不快感を生じにくい。 Moreover, the rose petal extract (fat metabolism improving agent) which concerns on this invention has the outstanding aroma peculiar to rose. In particular, even when taken orally, a mild aroma can be felt, and unpleasant tastes such as bitterness, astringency, and harshness are suppressed, so that excellent taste can be obtained as a whole. Therefore, it is hard to produce an unpleasant feeling in ingestion by various methods, such as oral.
＜バラ花弁抽出物＞
本発明に係るバラ花弁抽出物は、バラ科に属する植物の花弁の抽出物であればよいが、バラ亜科に属する植物の花弁の抽出物であるのが好ましく、バラ属に属する植物の花弁の抽出物であるのがより好ましい。
<Rose petal extract>
The rose petal extract according to the present invention may be an extract of the petals of a plant belonging to the family Rosaceae, but is preferably an extract of the petals of a plant belonging to the family Rosaceae, and the petals of a plant belonging to the genus Ros More preferably, it is an extract of
これにより、抽出物中の有効成分の含有率をより高いものとすることができ、複数の成分を含む抽出物全体としての脂肪代謝に関する作用をより高いものとすることができる。 As a result, the content of the active ingredient in the extract can be made higher, and the action on fat metabolism as a whole of the extract containing a plurality of components can be made higher.
バラ属に属するバラとしては、例えば、一重咲きのもの、半八重咲きのもの、八重咲きのもの等が挙げられ、これらから選択される１種または２種以上を組み合わせて用いてもよい。 Examples of the rose belonging to the genus Rose include single-flowered flowers, half-double-flowered flowers, double-flowered flowers, etc. One or two or more selected from these may be used in combination.
また、バラ属に属するバラの花型としては、例えば、平咲き、カップ咲き、ロゼット咲き、クオーター咲き、ポンポン咲き、剣弁高芯咲き、半剣弁高芯咲き、丸弁抱え咲き等が挙げられるが、これらのいずれのものを用いてもよく、また、２種以上を組み合わせて用いてもよい。 Moreover, as a rose flower type belonging to the genus Rose, for example, flat flowering, cup flowering, rosette flowering, quarter flowering, pom pom flowering, flowering high core flowering, half cored flower high core flowering, round valve holding flowering etc. However, any of these may be used, and two or more may be used in combination.
また、バラ属に属するバラには、一季咲きのもの、返り咲きのもの、繰り返し咲きのもの、四季咲きのものが挙げられるが、これらから選択される１種または２種以上を組み合わせて用いてもよい。 In addition, roses belonging to the genus Rose include those with seasonal flowers, those with reverse flowers, those with repeated flowers, those with seasonal flowers, but one or two or more selected from these may be used in combination. .
また、バラ属に属するバラの樹形としては、例えば、ブッシュ（木立性）、シュラブ（半つる性）、クライミング（つる性）等が挙げられるが、これらのいずれのものを用いてもよく、また、２種以上を組み合わせて用いてもよい。 In addition, as a tree form of a rose belonging to the genus Rose, for example, bush (tree standing), shrub (half climbing), climbing (climbing) etc. may be mentioned, but any of these may be used, Moreover, you may use combining 2 or more types.
バラ属に属するバラとしては、例えば、ロサ・アルバ（Ｒｏｓａ ａｌｂａ）、ロサ・カニナ（Ｒｏｓａ ｃａｎｉｎａ）、ロサ・ガリカ（Ｒｏｓａ ｇａｌｌｉｃａ）、ロサ・キナモメナ（Ｒｏｓａ ｃｉｎｎａｍｏｍｅａ）、ロサ・グラウカ（Ｒｏｓａ ｇｌａｕｃａ）、ロサ・センチフォリア（Ｒｏｓａ ｃｅｎｔｉｆｏｌｉａ）、ロサ・スピノシッシマ（Ｒｏｓａ ｓｐｉｎｏｓｉｓｓｉｍａ）、ロサ・ウィクライアナ（Ｒｏｓａ ｗｉｃｈｕｒａｉａｎａ）、ロサ・フェティダ（Ｒｏｓａ ｆｏｅｔｉｄａ）、ロサ・フェティダ・ビコロール（Ｒｏｓａ ｆｏｅｔｉｄａ ｂｉｃｏｌｏｒ）、ロサ・フェティダ・ペルシアナ（Ｒｏｓａ ｆｏｅｔｉｄａ ｐｅｒｓｉａｎａ）、ロサ・フェッチェンコアナ（Ｒｏｓａ ｆｅｄｔｓｃｈｅｎｋｏａｎａ）、ロサ・ダマスケナ（Ｒｏｓａ ｄａｍａｓｃｅｎａ）、コウシンバラ（Ｒｏｓａ ｃｈｉｎｅｎｓｉｓ）、ナニワイバラ（Ｒｏｓａ ｌａｅｖｉｇａｔａ）、ロサ・ギガンティア（Ｒｏｓａ ｇｉｇａｎｔｅａ）、ロサ・プリムラ（Ｒｏｓａ ｐｒｉｍｕｌａ）、ロサ・マリガニー（Ｒｏｓａ ｍｕｌｌｉｇａｎｉｉ）、ロサ・セリカナ・プテラカンサ（Ｒｏｓａ ｓｅｒｉｃａｎａ ｐｔｅｒａｃａｎｔｈａ）、ロサ・ユゴニス（Ｒｏｓａ ｈｕｇｏｎｉｓ）、ロサ・バンクシアエ・ルテア（Ｒｏｓａ ｂａｎｋｓｉａｅ ｌｕｔｅａ）（モッコウバラ）、ロサ・キネンシス（Ｒｏｓａ ｃｈｉｎｅｎｓｉｓ）、テリハノイバラ（照葉野茨）イザヨイバラ（Ｒｏｓａ ｒｏｘｂｕｒｇｈｉｉ）、サンショウバラ（Ｒｏｓａ ｈｉｒｔｕｌａ）、タカネイバラ（Ｒｏｓａ ａｃｉｃｕｌａｉｓｉｓ ｎｉｐｐｏｎｅｎｓｉｓ）、ノイバラ（Ｒｏｓａ ｍｕｌｔｉｆｌｏｒａ）、テリハノイバラ（Ｒｏｓａ ｗｉｃｈｕｒａｉａｎａ）、ハマナス（Ｒｏｓａ ｒｕｇｏｓａ）、サクライバラ（Ｒｏｓａ ｕｃｈｉｙａｍａｎａ）、モリイバラ（Ｒｏｓａ ｊａｓｍｉｎｏｉｄｅｓ）、フジイバラ（Ｒｏｓａ ｆｕｊｉｓａｎｅｎｓｉｓ）、ロサ・キンナモメア（Ｒｏｓａ ｃｉｎｎａｍｏｍｅａ）、ロサ・ニティダ（Ｒｏｓａ ｎｉｔｉｄａ）、ロサ・カリフォルニカ（Ｒｏｓａ ｃａｌｉｆｏｒｎｉｃａ）、ロサ・ヴィルギニアナ（Ｒｏｓａ ｖｉｒｇｉｎｉａｎａ）、ロサ・パルストリス（Ｒｏｓａ ｐａｌｕｓｔｒｉｓ）、ロサ・モスカータ（Ｒｏｓａ ｍｏｓｃｈａｔａ）等の原種（野生種）や、オールドローズ、モダンローズ等の園芸種が挙げられる。 Examples of the rose belonging to the genus Rose include Rosa alba (Rosa alba), Rosa canina (Rosa canina), Rosa gallica (Rosa gallica), Rosa cinchamomea, Rosa glauca, Rosa centifolia (Rosa centifolia), Rosa spinosissima, Rosa Wichriana (Rosa wichuraiana), Rosa fetida (Rosa foetida), Rosa fetida bicolo (Rosa foetida bicolor), Rosa fetida perna ( Rosa foetida persiana), Rosa fedtschenko ana), Rosa damascena, Rosa chinensis, Rosa laevigata, Rosa gigantea, Rosa primula, Rosa mariligani, Rosa Serikana pteracantha (Rosa sericana pteracantha), Rosa Hugonis (Rosa hugonis), Rosa Banksiae lutea (Rosa banksiae lutea) (mokkobara), Rosa Kinensis (Rosa chinensis), Terihanoibara (sunlight field moth) Isaiyoibabara (Rosa roxburgi) , Sanshobara (Rosa hirtula ), Takarabara (Rosa aciculaisis nipponensis), Nora (Rosa multiflora), Terihanoibara (Rosa wichuraiana), Hamanasu (Rosa rugosa), Sauribara (Rosa uchiyamana), Moriyabara (Rosa jasminoides), Fujiira (Rosa fujisanensis) Native species such as Rosa cinnamomea, Rosa nitida, Rosa californica, Rosa virginiana, Rosa palustris, Rosa moschata, etc. There are horticultural species such as raw species), old rose and modern rose.
オールドローズとしては、例えば、アルバ（Ａｌｂａ）、センチフォリア（Ｃｅｎｔｉｆｏｌｉａ）、ダマスク（Ｄａｍａｓｋ）、ガリカ（Ｇａｌｌｉｃａ）、ブルボン（Ｂｏｕｒｂｏｎ）、ノワゼット（Ｎｏｉｓｅｔｔｅ）、ティ（Ｔｅａ）、チャイナ（Ｃｈｉｎａ）、モス（Ｍｏｓｓ）、ポートランド（Ｐｏｒｔｌａｎｄ）、ポリアンサ（Ｐｏｌｙａｎｔｈａ）、ランブラー（Ｒａｍｂｌｅｒ）、エグラテリア・ローズ（Ｅｇｌａｎｔｅｒｉａ Ｒｏｓｅｓ）、ハイブリッド・パーペチュアル（Ｈ．Ｐｅｒｐｅｔｕａｌ）、ハイブリッド・フェティダ（Ｈ．Ｆｏｅｔｉｄａ）、ハイブリッド・マクランタ（Ｈ．Ｍａｃｒａｎｔｈａ）、ハイブリッド・ムスク（Ｈ．Ｍｕｓｋ）、ハイブリッド・モエシー（Ｈ．Ｍｏｙｅｓｉｉ）、ハイブリッド・センパビエレン（Ｈ．Ｓｅｍｐｅｒｖｉｒｅｎ）、ハイブリッド・ムルティフローラ（Ｈ．Ｍｕｌｔｉｆｌｏｒａ）、ハイブリッド・ルゴサ（Ｈ．Ｒｕｇｏｓａ）等が挙げられる。 As an old rose, for example, Alba (Alba), Centifolia (Centifolia), Damask (Damask), Galica (Gallica), Bourbon (Bourbon), Noisette (Noisette), Tea (Tea), China (China), Moss ( Moss, Portland (Portland), Polyantha (Polyantha), Rambler (Rambler), Eglanteria Roses (H. Perpetual), Hybrid Fetida (H. Foetida), Hybrid McLantha (H. Peretual) (Macrantha), hybrid musk (H. Musk), hybrid moesi (H. Moyesii), hybrid De Senpabieren (H.Semperviren), hybrid Murthy Flora (H.Multiflora), include the hybrid rugosa (H.Rugosa) and the like.
また、モダンローズとしては、例えば、ハイブリッド・ティー（Ｈｙｂｒｉｄ Ｔｅａ）、フロリバンダ（Ｆｌｏｒｉｂｕｎｄａ）、ミニチュア（Ｍｉｎｉａｔｕｒｅ）、つるハイブリッド・ティー（Ｃｌｉｍｂｉｎｇ Ｈｙｂｒｉｄ Ｔｅａ）、つるフロリバンダ（Ｃｌｉｍｂｉｎｇ Ｆｌｏｒｉｂｕｎｄａ）、つるミニチュア（Ｃｌｉｍｂｉｎｇ Ｍｉｎｉａｔｕｒｅ）、つる（Ｃｌｉｍｂｉｎｇ）、シュラブ（Ｓｈｒｕｂ）、イングリッシュ・ローズ（Ｅｎｇｌｉｓｈ Ｒｏｓｅｓ）、修景用（Ｌａｎｄｓｃａｐｅ Ｒｏｓｅｓ）、ハイブリッド・コルデシー（Ｈ．Ｋｏｒｄｅｓｉｉ）等が挙げられる。 In addition, as modern rose, for example, hybrid tea, Floribunda, Floribunda, Miniature, Climbing hybrid tea, Climbing floribunda, Climbing miniature Climbing, Shrub, English Roses, Landscape Roses, Hybrid Kordezii, and the like.
本発明の脂肪代謝改善剤は、バラ花弁抽出物を含んでいればよく、その他の成分、例えば、バラの花弁以外の部位の抽出物や、バラ由来の非抽出成分（例えば、製造過程で生じたバラ由来の微粉末等）等を含んでいてもよい。 The agent for improving metabolism of fat according to the present invention may contain rose petal extract, and other components such as extracts of sites other than petals of rose and non-extracted components derived from rose (for example, produced in the production process) Fine powder derived from rose, etc.) may be included.
ただし、本発明の脂肪代謝改善剤中におけるバラ花弁抽出物の含有率は、９０質量％以上であるのが好ましく、９５質量％以上であるのがより好ましく、９９質量％以上であるのがさらに好ましい。
これにより、前述したような効果がより顕著に発揮される。
However, the content of rose petal extract in the fat metabolism improving agent of the present invention is preferably 90% by mass or more, more preferably 95% by mass or more, and still more preferably 99% by mass or more preferable.
As a result, the effects as described above are more significantly exhibited.
本発明に係るバラ花弁抽出物は、いかなる方法、条件で抽出されたものであってもよいが、エタノールを含有する抽出溶媒による抽出物であるのが好ましい。 The rose petal extract according to the present invention may be extracted under any method and conditions, but is preferably an extract with an extraction solvent containing ethanol.
これにより、有効成分の抽出効率が高まり、単位重量の原料（バラ花弁抽出物）当たりの有効成分の抽出量を増やすことができるとともに、抽出物中に含まれる複数種の有効成分の含有率のバランスをより好適なものとすることができる。その結果、前述したような脂肪代謝改善効果がより顕著に発揮される。また、単位重量の原料から十分な量の有効成分を抽出するのに要する時間を短縮することができ、脂肪代謝改善剤の生産性を向上することができるとともに、脂肪代謝改善剤の製造過程における有効成分の劣化等を効果的に防止することができる。また、有効成分の抽出効率を高めつつ、不要成分の抽出を効果的に防止することができる。また、バラ花弁抽出物（脂肪代謝改善剤）の香気、風味等をより優れたものとすることができる。 As a result, the extraction efficiency of the active ingredient can be enhanced, and the extraction amount of the active ingredient per unit weight of raw material (rose petal extract) can be increased, and the content of the multiple active ingredients contained in the extract can be increased. The balance can be made more favorable. As a result, the fat metabolism improving effect as described above is more significantly exhibited. In addition, the time required to extract a sufficient amount of active ingredient from a unit weight of raw material can be shortened, the productivity of the fat metabolism improving agent can be improved, and in the process of producing the fat metabolism improving agent Deterioration or the like of the active ingredient can be effectively prevented. In addition, the extraction of unnecessary components can be effectively prevented while enhancing the extraction efficiency of the active components. In addition, the aroma, flavor and the like of the rose petal extract (fat metabolism improving agent) can be made more excellent.
なお、本発明の脂肪代謝改善剤の製造方法（バラ花弁抽出物の抽出方法を含む）については、後に詳述する。 The method for producing a fat metabolism improving agent of the present invention (including a method for extracting a rose petal extract) will be described in detail later.
本発明の脂肪代謝改善剤は、粉末状（顆粒を含む）、フィルム状、液状、ペースト状等、いかなる形状のものであってもよいが、粉末状をなすものであるのが好ましい。 The fat metabolism improving agent of the present invention may be in any form such as powder (including granules), film, liquid, paste and the like, but is preferably in powder form.
これにより、脂肪代謝改善剤を経口で摂取した場合に、脂肪代謝改善効果がより顕著に発揮され易くなる。また、脂肪代謝改善剤を後述するような本発明の組成物、成形体の製造により好適に用いることができる。また、脂肪代謝改善剤の生産性をより優れたものとすることができる。 Thereby, when the fat metabolism improving agent is orally taken, the fat metabolism improving effect is more easily exhibited. In addition, the fat metabolism improving agent can be more suitably used for the production of the composition and molded article of the present invention as described later. In addition, the productivity of the fat metabolism improving agent can be further improved.
本発明の脂肪代謝改善剤が粉末状をなすものである場合、その平均粒径は、特に限定されないが、１μｍ以上５０００μｍ以下であるのが好ましく、１０μｍ以上３０００μｍ以下であるのがより好ましく、１００μｍ以上１０００μｍ以下であるのがさらに好ましい。 When the fat metabolism improving agent of the present invention is in the form of powder, its average particle size is not particularly limited, but it is preferably 1 to 5000 μm, more preferably 10 to 3000 μm, and 100 μm. More preferably, it is at least 1000 μm.
これにより、脂肪代謝改善剤を経口で摂取した場合に、脂肪代謝改善効果がさらに顕著に発揮され易くなる。また、脂肪代謝改善剤を後述するような本発明の組成物、成形体の製造にさらに好適に用いることができる。また、脂肪代謝改善剤の生産性をさらに優れたものとすることができる。 Thereby, when the fat metabolism improving agent is orally taken, the fat metabolism improving effect is more easily exhibited. In addition, the fat metabolism improving agent can be more suitably used for the production of the composition and molded article of the present invention to be described later. In addition, the productivity of the fat metabolism improving agent can be further improved.
なお、本明細書において、平均粒径とは、特に断りのない限り、体積平均粒径のことを言う。 In the present specification, the average particle size refers to the volume average particle size unless otherwise noted.
［脂肪代謝改善剤の製造方法］
次に、本発明の脂肪代謝改善剤の製造方法について説明する。
[Method for producing fat metabolism improving agent]
Next, the method for producing the fat metabolism improving agent of the present invention will be described.
本発明の脂肪代謝改善剤の製造方法は、エタノールを含有する抽出溶媒と、バラの花弁とを接触させて、バラ花弁の含有成分を抽出する抽出工程を有することを特徴とする。 The method for producing a fat metabolism improving agent of the present invention is characterized by comprising an extraction step of bringing an extractant containing ethanol into contact with a rose petal to extract an ingredient of the rose petal.
これにより、前述したような脂肪代謝改善剤を効率よく製造することができる脂肪代謝改善剤の製造方法を提供することができる。また、有効成分の抽出効率が高まり、単位重量の原料（バラ花弁抽出物）当たりの有効成分の抽出量を増やすことができるとともに、抽出物中に含まれる複数種の有効成分の含有率のバランスをより好適なものとすることができる。その結果、前述したような脂肪代謝改善効果がより顕著に発揮される。また、有効成分の抽出効率を高めつつ、不要成分の抽出を効果的に防止することができる。また、バラ花弁抽出物（脂肪代謝改善剤）の香気、風味等をより優れたものとすることができる。 Thus, it is possible to provide a method for producing a fat metabolism improving agent capable of efficiently producing a fat metabolism improving agent as described above. In addition, the extraction efficiency of the active ingredient is enhanced, and the extraction amount of the active ingredient per unit weight of raw material (rose petal extract) can be increased, and the balance of the contents of the plurality of active ingredients contained in the extract is balanced. Can be more preferable. As a result, the fat metabolism improving effect as described above is more significantly exhibited. In addition, the extraction of unnecessary components can be effectively prevented while enhancing the extraction efficiency of the active components. In addition, the aroma, flavor and the like of the rose petal extract (fat metabolism improving agent) can be made more excellent.
＜抽出工程＞
抽出工程では、エタノールを含有する抽出溶媒と、バラの花弁とを接触させて、バラ花弁の含有成分を抽出する。
<Extraction process>
In the extraction step, an ethanol-containing extraction solvent is brought into contact with a rose petal to extract the ingredients of the rose petal.
本工程では、例えば、摘み取ったバラの花弁をそのまま用いてもよいし、バラの花弁に予め前処理を施したものを用いてもよい。 In this step, for example, the picked petals of a rose may be used as it is, or the petals of a rose may be pretreated.
バラの花弁に対する前処理としては、例えば、洗浄処理、乾燥処理、凍結処理、加熱処理、粉砕処理、揉処理、発酵処理等が挙げられる。 Examples of pretreatment for the petals of rose include washing treatment, drying treatment, freezing treatment, heat treatment, grinding treatment, chewing treatment, fermentation treatment and the like.
抽出溶媒とバラの花弁との接触は、いかなる方法で行ってもよく、例えば、バラの花弁と抽出溶媒とを混合した後、有効成分の活性を失活させない程度に加温加熱する加熱抽出法や、超臨界抽出法等を採用することできる。また、所定量の抽出溶媒にバラの花弁を浸漬してバッチ処理する浸漬抽出法や連続的にバラの花弁を送り続ける連続抽出法等を採用することができる。 The contact between the extraction solvent and the petals of rose may be carried out by any method, for example, a heating extraction method in which after mixing the petals of rose and the extraction solvent, heating and heating to such an extent that the activity of the active ingredient is not inactivated. Or, supercritical extraction method etc. can be adopted. Further, it is possible to adopt an immersion extraction method in which rose petals are immersed in a predetermined amount of extraction solvent and subjected to batch processing, a continuous extraction method in which rose petals are continuously fed, or the like.
特に、本工程は、バラの花弁を前記抽出溶媒中に浸漬すること（浸漬抽出法）により行うのが好ましい。 In particular, this step is preferably performed by immersing petals of rose in the extraction solvent (immersion extraction method).
これにより、低コストで、有効成分の抽出効率を高めることができ、単位重量の原料（バラ花弁抽出物）当たりの有効成分の抽出量を増やすことができるとともに、抽出物中に含まれる複数種の有効成分の含有率のバランスをより好適なものとすることができる。その結果、前述したような脂肪代謝改善効果がより顕著に発揮される。また、有効成分の抽出効率を高めつつ、不要成分の抽出をより効果的に防止することができる。また、バラ花弁抽出物（脂肪代謝改善剤）の香気、風味等をより優れたものとすることができる。 As a result, the extraction efficiency of the active ingredient can be increased at low cost, and the extraction amount of the active ingredient per unit weight of raw material (rose petal extract) can be increased, and a plurality of types contained in the extract can be obtained. The balance of the content of the active ingredient can be made more preferable. As a result, the fat metabolism improving effect as described above is more significantly exhibited. Moreover, extraction of unnecessary components can be more effectively prevented while enhancing the extraction efficiency of the active components. In addition, the aroma, flavor and the like of the rose petal extract (fat metabolism improving agent) can be made more excellent.
抽出溶媒は、エタノールを含有していればよいが、抽出溶媒中におけるエタノールの含有率は、２体積％以上８０体積％以下が好ましく、８体積％以上７０体積％以下がより好ましく、１４体積％以上６０体積％以下がさらに好ましい。 The extraction solvent may contain ethanol, but the content of ethanol in the extraction solvent is preferably 2 vol% to 80 vol%, more preferably 8 vol% to 70 vol%, and 14 vol%. More than 60 volume% is more preferable.
これにより、有効成分の抽出効率がさらに高まり、単位重量の原料（バラ花弁抽出物）当たりの有効成分の抽出量をさらに増やすことができるとともに、抽出物中に含まれる複数種の有効成分の含有率のバランスをより好適なものとすることができる。その結果、前述したような脂肪代謝改善効果がより顕著に発揮される。また、単位重量の原料から十分な量の有効成分を抽出するのに要する時間をさらに短縮することができ、脂肪代謝改善剤の生産性をさらに向上することができるとともに、脂肪代謝改善剤の製造過程における有効成分の劣化等をより効果的に防止することができる。また、有効成分の抽出効率を高めつつ、不要成分の抽出をより効果的に防止することができる。また、バラ花弁抽出物（脂肪代謝改善剤）の香気、風味等をさらに優れたものとすることができる。 As a result, the extraction efficiency of the active ingredient is further enhanced, and the extraction amount of the active ingredient per unit weight of raw material (rose petal extract) can be further increased, and the contents of plural kinds of active ingredients contained in the extract are contained. The balance of rates can be made more suitable. As a result, the fat metabolism improving effect as described above is more significantly exhibited. In addition, the time required to extract a sufficient amount of active ingredient from a unit weight of raw material can be further shortened, and the productivity of the fat metabolism improving agent can be further improved, and the production of the fat metabolism improving agent Deterioration and the like of the active ingredient in the process can be more effectively prevented. Moreover, extraction of unnecessary components can be more effectively prevented while enhancing the extraction efficiency of the active components. Further, the aroma, flavor and the like of the rose petal extract (fat metabolism improving agent) can be further improved.
また、抽出溶媒は、エタノールに加え、水を含む混合溶媒であるのが好ましい。
これにより、水溶性に優れたバラ花弁抽出物（脂肪代謝改善剤）を得ることができ、その後の処理が容易になるとともに、バラ花弁抽出物（脂肪代謝改善剤）の生体吸収性をより優れたものとすることができる。また、有効成分の抽出効率がさらに高まり、単位重量の原料（バラ花弁抽出物）当たりの有効成分の抽出量をさらに増やすことができるとともに、抽出物中に含まれる複数種の有効成分の含有率のバランスをより好適なものとすることができる。その結果、前述したような脂肪代謝改善効果がより顕著に発揮される。また、単位重量の原料から十分な量の有効成分を抽出するのに要する時間をさらに短縮することができ、脂肪代謝改善剤の生産性をさらに向上することができるとともに、脂肪代謝改善剤の製造過程における有効成分の劣化等をより効果的に防止することができる。また、有効成分の抽出効率を高めつつ、不要成分の抽出をより効果的に防止することができる。また、バラ花弁抽出物（脂肪代謝改善剤）の香気、風味等をさらに優れたものとすることができる。
The extraction solvent is preferably a mixed solvent containing water in addition to ethanol.
As a result, it is possible to obtain a rose petal extract (fat metabolism improving agent) excellent in water solubility, and subsequent processing becomes easy, and at the same time, the bioabsorbability of the rose petal extract (fat metabolism improving agent) is more excellent It can be In addition, the extraction efficiency of the active ingredient is further enhanced, and the extraction amount of the active ingredient per unit weight of raw material (rose petal extract) can be further increased, and the contents of plural kinds of active ingredients contained in the extract Balance can be made more preferable. As a result, the fat metabolism improving effect as described above is more significantly exhibited. In addition, the time required to extract a sufficient amount of active ingredient from a unit weight of raw material can be further shortened, and the productivity of the fat metabolism improving agent can be further improved, and the production of the fat metabolism improving agent Deterioration and the like of the active ingredient in the process can be more effectively prevented. Moreover, extraction of unnecessary components can be more effectively prevented while enhancing the extraction efficiency of the active components. Further, the aroma, flavor and the like of the rose petal extract (fat metabolism improving agent) can be further improved.
抽出溶媒中における水の含有率は、２０体積％以上９５体積％以下が好ましく、３０体積％以上９０体積％以下がより好ましく、４０体積％以上８５体積％以下がさらに好ましい。 20 volume% or more and 95 volume% or less are preferable, as for the content rate of water in an extraction solvent, 30 volume% or more and 90 volume% or less are more preferable, and 40 volume% or more and 85 volume% or less are more preferable.
これにより、バラ花弁抽出物（脂肪代謝改善剤）の水溶性をさらに向上させることができる。有効成分の抽出効率がさらに高まり、単位重量の原料（バラ花弁抽出物）当たりの有効成分の抽出量をさらに増やすことができるとともに、抽出物中に含まれる複数種の有効成分の含有率のバランスをさらに好適なものとすることができる。その結果、前述したような脂肪代謝改善効果がさらに顕著に発揮される。また、単位重量の原料から十分な量の有効成分を抽出するのに要する時間をさらに短縮することができ、脂肪代謝改善剤の生産性をさらに向上することができるとともに、脂肪代謝改善剤の製造過程における有効成分の劣化等をさらに効果的に防止することができる。また、有効成分の抽出効率を高めつつ、不要成分の抽出をさらに効果的に防止することができる。また、バラ花弁抽出物（脂肪代謝改善剤）の香気、風味等をさらに優れたものとすることができる。 Thereby, the water solubility of the rose petal extract (fat metabolism improving agent) can be further improved. The extraction efficiency of the active ingredient is further enhanced, and the extraction amount of the active ingredient per unit weight of raw material (rose petal extract) can be further increased, and the balance of the contents of the plurality of active ingredients contained in the extract is balanced. Can be further preferred. As a result, the fat metabolism improving effect as described above is more significantly exhibited. In addition, the time required to extract a sufficient amount of active ingredient from a unit weight of raw material can be further shortened, and the productivity of the fat metabolism improving agent can be further improved, and the production of the fat metabolism improving agent Deterioration and the like of the active ingredient in the process can be further effectively prevented. Moreover, extraction of unnecessary components can be further effectively prevented while enhancing the extraction efficiency of the active components. Further, the aroma, flavor and the like of the rose petal extract (fat metabolism improving agent) can be further improved.
また、抽出溶媒は、エタノールおよび水以外の成分を含むものであってもよいが、エタノールおよび水以外の成分（その他の成分）の含有率は、３体積％以下であるのが好ましく、２体積％以下であるのがより好ましく、１体積％以下であるのがさらに好ましい。 The extraction solvent may contain components other than ethanol and water, but the content of components other than ethanol and water (other components) is preferably 3% by volume or less, and 2 volumes % Or less is more preferable, and 1% by volume or less is even more preferable.
また、抽出溶媒のｐＨは、４．０以上９．０以下が好ましく、４．５以上８．５以下がより好ましく、５．０以上８．０以下がさらに好ましい。 The pH of the extraction solvent is preferably 4.0 or more and 9.0 or less, more preferably 4.5 or more and 8.5 or less, and still more preferably 5.0 or more and 8.0 or less.
これにより、有効成分の不本意な変性等を効果的に防止し、より好適な組成の抽出物をさらに効率的に得ることができる。 By this, it is possible to effectively prevent unintentional denaturation and the like of the active ingredient and to more efficiently obtain an extract having a more preferable composition.
抽出温度は、特に限定されないが、５℃以上８０℃以下であるのが好ましく、１０℃以上６０℃以下であるのがより好ましく、１５℃以上５０℃以下であるのがさらに好ましい。 The extraction temperature is not particularly limited, but is preferably 5 ° C. or more and 80 ° C. or less, more preferably 10 ° C. or more and 60 ° C. or less, and still more preferably 15 ° C. or more and 50 ° C. or less.
これにより、有効成分の不本意な変性等を効果的に防止し、より好適な組成の抽出物を短時間で効率的に得ることができ、脂肪代謝改善剤の生産性をより向上させることができる。 By this, it is possible to effectively prevent undesired denaturation of the active ingredient, to efficiently obtain an extract having a more suitable composition in a short time, and to improve the productivity of the fat metabolism improving agent. it can.
また、抽出時間は、特に限定されないが、１時間以上１０日間以下であるのが好ましく、３時間以上７日間以下であるのがより好ましく、５時間以上５日間以下であるのがさらに好ましい。 The extraction time is not particularly limited, but is preferably 1 hour to 10 days, more preferably 3 hours to 7 days, and still more preferably 5 hours to 5 days.
これにより、有効成分の不本意な変性等を効果的に防止し、より好適な組成の抽出物をさらに効率的に得ることができ、脂肪代謝改善剤の生産性をより向上させることができる。 By this, it is possible to effectively prevent unwanted denaturation and the like of the active ingredient, to more efficiently obtain an extract having a more suitable composition, and to further improve the productivity of the fat metabolism improving agent.
特に、本工程を浸漬抽出法により行い場合、抽出時間（抽出溶媒への浸漬時間）は、６時間以上１０日間以下であるのが好ましく、１２時間以上７日間以下であるのがより好ましく、１日間以上５日間以下であるのがさらに好ましい。 In particular, when the present step is performed by the immersion extraction method, the extraction time (immersion time to the extraction solvent) is preferably 6 hours to 10 days, and more preferably 12 hours to 7 days, 1 More preferably, it is not less than a day and not more than 5 days.
＜後処理工程＞
上記のような抽出工程の後、必要に応じて、後処理工程を行ってもよい。
<Post-processing process>
After the extraction step as described above, a post-treatment step may be carried out, if necessary.
後処理工程としては、例えば、抽出液中に含まれる異物である固形分を、濾過、デカンテーション、遠心分離等により除去する固形分除去処理を行う固形分除去工程、溶媒の少なくとも一部を除去する濃縮処理を行う濃縮工程、抽出物中に含まれる成分の少なくとも一部に対して、化学構造の変換を伴う化学反応処理を行う化学反応工程、抽出物中に含まれる不要成分の少なくとも一部を除去する精製処理を行う精製工程、得られた抽出物を所定の形状に成形する成形処理を施す成形工程等が挙げられ、これらのうち１つまたは２つ以上を組み合わせて行ってもよい。 In the post-treatment step, for example, a solid content removing step of removing solid content, which is a foreign matter contained in the extract, by filtration, decantation, centrifugation or the like, removing at least a part of the solvent Concentration step of performing concentration treatment, chemical reaction step of performing chemical reaction treatment involving conversion of chemical structure to at least a portion of components contained in the extract, at least a portion of unnecessary components contained in the extract The purification process which performs the purification process which removes, the formation process which performs the formation process which shape | molds the obtained extract into a predetermined shape, etc. are mentioned, You may carry out combining one or two or more of these.
例えば、化学反応工程を行うことにより、抽出物中に含まれる有効成分以外の成分（例えば、有効成分の前駆体等の非有効成分）を有効成分に変換することにより、最終的に得られる脂肪代謝改善剤中における有効成分の含有率を高めたり、複数種の有効成分の比率がより好適なものとなるように調整することができる。また、抽出物中に含まれる有効成分についても、化学反応を行ってもよい。これにより、例えば、抽出物中に含まれる複数種の有効成分の比率がより好適なものとなるように調整することができる。 For example, fat which is finally obtained by converting a component other than the active ingredient contained in the extract (for example, an inactive ingredient such as a precursor of the active ingredient) into the active ingredient by performing a chemical reaction step. The content of the active ingredient in the metabolism improving agent can be increased, or the ratio of the plurality of active ingredients can be adjusted to be more suitable. Chemical reaction may also be performed on the active ingredient contained in the extract. Thereby, for example, the ratio of the plurality of active ingredients contained in the extract can be adjusted to be more suitable.
精製工程で行う精製処理としては、例えば、分液漏斗等を用いた分液処理、薄層クロマトグラフィー（ＴＬＣ）やカラムクロマトグラフィー（高速液体クロマトグラフィー（ＨＰＬＣ）、ゲル浸透クロマトグラフィー（ＧＰＣ）等を含む）等が挙げられる。 Examples of the purification treatment to be carried out in the purification step include separation treatment using a separatory funnel etc., thin layer chromatography (TLC), column chromatography (high performance liquid chromatography (HPLC), gel permeation chromatography (GPC), etc. And the like).
上記のうち少なくとも１つの工程は、例えば、異なるタイミングで複数回行ってもよい。例えば、濃縮工程を複数回行う場合、前記抽出工程で得られた抽出溶媒を含む抽出物に対して行い（第１の濃縮工程）、その後に行う精製工程後に、再度、精製工程で用いた溶媒（溶離液、展開溶媒等）を除去する濃縮工程（第２の濃縮工程）を行ってもよい。 At least one of the above steps may be performed, for example, multiple times at different timings. For example, when the concentration step is performed a plurality of times, it is performed on the extract containing the extraction solvent obtained in the extraction step (first concentration step), and after the purification step performed thereafter, the solvent used in the purification step again A concentration step (second concentration step) of removing (eluent, developing solvent, etc.) may be performed.
また、精製工程を複数回行う場合、例えば、分液漏斗等を用いた分液処理を行う精製工程（第１の精製工程）と、カラムクロマトグラフィーを用いた精製処理を行う精製工程（第２の精製工程）とを組み合わせて行ってもよい。第１の精製工程と、第２の精製工程との間には、濃縮工程を行ってもよい。 In addition, in the case where the purification step is performed a plurality of times, for example, a purification step (first purification step) in which liquid separation processing is performed using a separatory funnel or the like, and a purification step in which purification processing using column chromatography is performed (second And the purification step of A concentration step may be performed between the first purification step and the second purification step.
カラムクロマトグラフィーで用いる充填材としては、例えば、イオン交換樹脂、合成吸着樹脂、活性炭、キレート樹脂、シリカゲル、アルミナ、デキストランや、これらの修飾体（例えば、オクタデシル化シリカゲル（ＯＤＳ）、ヒドロキシプロピル化デキストラン等）等が挙げられる。 Examples of the packing material used in column chromatography include ion exchange resin, synthetic adsorption resin, activated carbon, chelate resin, silica gel, alumina, dextran, and modified products thereof (eg, octadecylated silica gel (ODS), hydroxypropylated dextran Etc.).
各種クロマトグラフィーにおける溶離液・展開溶媒としては、例えば、水、水溶性溶媒、低極性溶媒、無極性溶媒等を用いることができ、２種以上の溶媒の混合物（混合溶媒）を用いてもよい。 As an eluent / developing solvent in various chromatography, for example, water, a water-soluble solvent, a low polar solvent, a nonpolar solvent and the like can be used, and a mixture of two or more solvents (mixed solvent) may be used. .
水溶性溶媒としては、例えば、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール等の１価のアルコール；１，３−ブチレングリコール、プロピレングリコール、グリセリン等の多価アルコール；アセトン、メチルエチルケトン等のケトン；アセトニトリル等が挙げられるが、炭素数１以上５以下の１価のアルコールが好ましく、メタノール、エタノールがより好ましい。 Examples of the water-soluble solvent include monohydric alcohols such as methanol, ethanol, propyl alcohol and isopropyl alcohol; polyhydric alcohols such as 1,3-butylene glycol, propylene glycol and glycerin; ketones such as acetone and methyl ethyl ketone; However, monohydric alcohols having 1 to 5 carbon atoms are preferable, and methanol and ethanol are more preferable.
特に、溶離液・展開溶媒としては、水と水溶性溶媒との混合溶媒を用いるのが好ましく、水とエタノールとの混合溶媒を用いるのがより好ましい。 In particular, as the eluent / developing solvent, a mixed solvent of water and a water-soluble solvent is preferably used, and a mixed solvent of water and ethanol is more preferably used.
溶離液・展開溶媒として水とエタノールとの混合溶媒を用いる場合、当該混合溶媒中におけるエタノールの含有率は、２０体積％以上９５体積％以下が好ましく、３０体積％以上９０体積％以下がより好ましく、４０体積％以上８５体積％以下がさらに好ましい。 When a mixed solvent of water and ethanol is used as the eluent / developing solvent, the content of ethanol in the mixed solvent is preferably 20% by volume or more and 95% by volume or less, and more preferably 30% by volume or more and 90% by volume or less 40% by volume or more and 85% by volume or less is more preferable.
これにより、不要成分を効率よく除去することができ、より好適な組成の抽出物を容易に得ることができる。 Thereby, an unnecessary component can be removed efficiently and the extract of a more suitable composition can be obtained easily.
溶離液・展開溶媒として水とエタノールとの混合溶媒を用いる場合、当該混合溶媒中における水の含有率は、２体積％以上８０体積％以下が好ましく、８体積％以上７０体積％以下がより好ましく、１４体積％以上６０体積％以下がさらに好ましい。 When a mixed solvent of water and ethanol is used as the eluent / developing solvent, the content of water in the mixed solvent is preferably 2% by volume to 80% by volume, more preferably 8% by volume to 70% by volume 14% by volume or more and 60% by volume or less is more preferable.
これにより、不要成分を効率よく除去することができ、より好適な組成の抽出物を容易に得ることができる。 Thereby, an unnecessary component can be removed efficiently and the extract of a more suitable composition can be obtained easily.
濃縮処理を行う場合、当該濃縮処理としては、例えば、エバポレーターを用いた処理、噴霧乾燥（スプレードライ）、真空乾燥、凍結乾燥等の方法が挙げられる。 When the concentration treatment is performed, examples of the concentration treatment include treatment using an evaporator, spray drying (spray drying), vacuum drying, and lyophilization.
［組成物、成形体］
次に、本発明の組成物、成形体について説明する。
[Composition, molding]
Next, the composition and the molded article of the present invention will be described.
本発明の組成物および成形体は、前述したような本発明に係る脂肪代謝改善剤に加え、他の成分（その他の成分）を含有することを特徴とする。 The composition and molded body of the present invention are characterized by containing other components (other components) in addition to the fat metabolism improving agent according to the present invention as described above.
これにより、細胞レベルでの総合的な脂肪代謝を効果的に改善する脂肪代謝改善剤を含有する組成物、成形体を提供することができる。特に、脂肪代謝改善効果を得つつ、その他の成分に対応する機能を発揮させることができ、例えば、食品や医薬品、医薬部外品等の各種組成物、各種成形体に好適に適用することができる。 This makes it possible to provide a composition and a molded body containing a fat metabolism improving agent that effectively improves overall fat metabolism at the cellular level. In particular, it can exhibit a function corresponding to other components while obtaining a fat metabolism improving effect, and for example, it can be suitably applied to various compositions such as foods, medicines, quasi-drugs and various molded articles. it can.
また、上記のように、本発明に係るバラ花弁抽出物（脂肪代謝改善剤）は、バラ特有の優れた香気を有しており、穏やかな香気を感じることができ、かつ、苦み、渋み、えぐみ等の不快な味覚は抑えられており、全体として優れた風味が得られる。したがって、本発明の組成物、成形体においても、上記のような効果が得られる。 In addition, as described above, the rose petal extract (fat metabolism improving agent) according to the present invention has an excellent aroma specific to rose, can feel a mild aroma, and is bitter, astringent, Unpleasant taste such as eel is suppressed, and an excellent flavor is obtained as a whole. Therefore, the effects as described above can be obtained also in the composition and the molded body of the present invention.
また、本発明に係るバラ花弁抽出物（脂肪代謝改善剤）自体が、優れた香気、風味を有しているため、矯味剤や香料等を使用しなかったり、矯味剤の使用量を抑制した場合であっても、本発明の組成物、成形体全体としての風味等を優れたものとすることができる。 In addition, since the rose petal extract (fat metabolism improving agent) itself according to the present invention has excellent aroma and flavor, it does not use a flavoring agent, a flavoring agent or the like, or the amount of flavoring agent used is suppressed. Even when it is the case, the composition of the present invention, the flavor and the like as a whole of the molded product can be made excellent.
本発明の成形体は、所定の形状に成形されたものである。
成形体を得るための成形方法は、特に限定されないが、例えば、圧縮成形、圧粉成形（打錠を含む）、押出成形、射出成形、カプセルへの充填、三次元造形法による成形等が挙げられる。
The molded body of the present invention is molded into a predetermined shape.
The molding method for obtaining a molded body is not particularly limited, and examples thereof include compression molding, powder compacting (including tableting), extrusion molding, injection molding, filling into capsules, and molding by a three-dimensional shaping method. Be
本発明の組成物、成形体の動物への投与方法は、特に限定されないが、例えば、経口投与、頬側投与、舌下投与、直腸投与、血管内投与（静脈内投与、動脈内投与等）、骨内投与、筋肉内投与、脳内投与、脳室内投与、髄腔内投与、皮下投与、腹腔内投与、眼内投与、鼻腔内投与、気管内投与、気管支内投与、経真皮投与、硬膜外投与、頭蓋内投与、経皮投与、膣内投与、子宮内投与、硝子体内投与、経粘膜投与等が挙げられる。 The composition of the present invention and the method of administering the shaped body to an animal are not particularly limited. For example, oral administration, buccal administration, sublingual administration, rectal administration, intravascular administration (intravenous administration, intraarterial administration, etc.) Intraosseous administration, intramuscular administration, intracerebral administration, intracerebroventricular administration, intrathecal administration, subcutaneous administration, subcutaneous administration, intraperitoneal administration, intraocular administration, intranasal administration, intratracheal administration, intrabronchial administration, dermal administration, hard Extramural administration, intracranial administration, transdermal administration, intravaginal administration, intrauterine administration, intravitreal administration, transmucosal administration and the like can be mentioned.
特に、本発明の組成物、成形体は、口腔内に付与して用いられる経口物であるのが好ましい。 In particular, the composition and molded body of the present invention are preferably orally administered for use in the oral cavity.
経口物としては、例えば、食品、内服薬、吸入薬等の経口医薬品等のように口腔内に付与された後に、その大部分が食道、気道等の体腔（口腔以外の体腔）に導入されるものや、口腔用錠剤（舌下錠等）、口腔用軟膏等の経口医薬品のようにその大部分が口腔内の粘膜から吸収されるもの、歯磨き、うがい薬、洗口剤等の口腔ケア製品、噛みたばこ、ガム等のように一旦口腔内に付与した後に、その大部分が口から体外に排出されるもの等が挙げられる。 As the oral product, for example, food, oral medication, oral medicine such as inhalant, etc. after being given in the oral cavity, most of which is introduced into body cavity such as esophagus or airway (body cavity other than oral cavity) And oral care products such as oral tablets such as oral tablets (sublingual tablets, etc.) and oral ointments, the majority of which are absorbed from mucous membranes in the oral cavity, oral care products such as toothpaste, mouthwash, mouthwash, etc. There is a chewing tobacco, a gum and the like which is given in the oral cavity once and then the majority is excreted from the mouth and the like.
組成物、成形体の用途としては、例えば、食品；嗜好品（例えば、噛みたばこ等）；歯磨き、うがい薬、洗口剤等の口腔ケア製品；医薬品；医薬部外品；石鹸、ボディーソープ、手洗い用洗剤（ハンドソープ）、食器用洗剤、衣類用洗剤（柔軟剤を含む）、浴室用洗剤、トイレ用洗剤、ガラス用洗剤、車両用洗剤等の各種洗剤；シャンプー、リンス、コンディショナー、トリートメント、整髪料、毛染め剤、育毛剤、セッティング剤・スタイル保持剤（例えば、ジェル、ムース、スプレー等）、ポマード等のヘアケア製品；化粧水、クリーム、乳液、美容液、美白剤、洗顔料（洗顔用クレンザーを含む）等のスキンケア製品；リップクリーム、口紅等のリップ用製品；化粧下地、チーク、ファンデーションクリーム、マスカラ等の化粧品；ポリッシュ、ポリッシュリムーバー、ストレンスナー、レングスナー、ハードナー、キューティクルリムーバー、ソフナー等のネイルケア製品；シェービングクリームおよびローション、脱毛剤、髭剃り後のスキンコンディショナー等の脱毛関連製品；その他、アンチエイジング剤、制汗剤、日焼け止め剤、日焼け促進剤、香水、各種ワックス、入浴剤、冷却用スプレー等の冷却剤等が挙げられる。 Composition, use of molded articles include, for example, food; luxury goods (eg, chewing tobacco etc.); oral care products such as toothpaste, mouthwash, mouthwash etc .; pharmaceuticals; quasi-drugs; soap, body soap, Various detergents such as hand washing detergents (hand soaps), dish detergents, clothing detergents (including softeners), bathroom detergents, toilet detergents, glass detergents, vehicle detergents, etc .; shampoos, rinses, conditioners, treatments, Hair-setting agents, hair-dying agents, hair-growth agents, setting agents / style keeping agents (eg, gel, mousse, spray, etc.), hair care products such as pomades; lotions, creams, emulsions, essences, skin-whitening agents, face-washing agents Skin care products such as cleansers); lip products such as lip balms and lipsticks; cosmetics such as makeup substrates, cheeks, foundation creams and mascara; Care products such as wash, polish remover, strengthner, lengthener, hardener, cuticle remover, softener, etc .; shaving cream and lotion, depilatory, hair removal related products such as skin conditioner after shaving; other, anti-aging, antiperspirant And sunscreen agents, sunscreen agents, perfumes, various waxes, bath agents, cooling agents such as cooling sprays, and the like.
なお、食品の形態には、固形状、半固形状（ゼリー、プリン等のゲル状等）に加え、液状が含まれ、食品は、飲み物等も含む概念である。また、調味料や風味剤、食品添加物、サプリメント（健康補助食品）も食品の概念に含まれる。 In addition to solid and semi-solid forms (gel, gel form such as pudding, etc.), the form of food includes liquid, and food is a concept including drinks and the like. Also included in the food concept are seasonings and flavors, food additives, supplements (health supplements).
本発明に係る組成物、成形体を医薬品や医薬部外品に適用する場合、錠剤、散剤、細粒剤、顆粒剤、カプセル剤、シロップ剤等の経口剤、坐剤、軟膏、噴霧剤、注射剤、点滴剤、スプレー剤、点眼剤、経鼻投与剤、貼付剤等の非経口剤の形態とすることができる。 When the composition according to the present invention or the molded body is applied to a drug or quasi drug, it can be tablets, powders, fine granules, granules, capsules, oral preparations such as capsules, syrups, suppositories, ointments, sprays, It can be in the form of parenteral preparations such as injections, drops, sprays, eye drops, intranasal preparations, patches and the like.
前記他の成分として、例えば、賦形剤、増粘剤、ゲル化剤、ｐＨ調整剤、酸化防止剤、着色剤、充填剤、結合剤、凝固剤、滑たく剤、ステアリン酸マグネシウム等の潤滑剤、繊維素グリコール酸カルシウム等の崩壊剤、ラクトース等の安定化剤、グルタミン酸、アスパラギン酸等の溶解補助剤、乳糖、マンニトール、ブドウ糖、ヒドロキシプロピルセルロース、微結晶セルロース、デンプン、ポリビニルピロリドン、メタケイ酸アルミン酸マグネシウム等の希釈剤、防腐剤、湿潤剤、乳化剤、分散剤、乳濁剤、溶液剤、懸濁剤、エリキシル剤、風味剤、芳香剤、甘味料、清涼化剤、香料、矯味剤、コーティング剤、他の有効成分（薬効成分）等を含ませてもよい。 Examples of the other components include lubricating agents such as excipients, thickeners, gelling agents, pH adjusters, antioxidants, colorants, fillers, binders, coagulants, lubricants, magnesium stearate and the like. Agents, disintegrants such as calcium fibril glycolate, stabilizers such as lactose, solubilizers such as glutamic acid and aspartic acid, lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinyl pyrrolidone, metasilicic acid Diluents such as magnesium aluminate, preservatives, wetting agents, emulsifiers, dispersants, emulsions, solutions, suspensions, elixirs, flavors, fragrances, sweeteners, refreshing agents, flavors, flavors , Coating agents, other active ingredients (drug ingredients), etc. may be included.
特に、本発明を錠剤に適用する場合、例えば、ショ糖、ゼラチン、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロースフタレート等の糖衣、または胃溶性もしくは腸溶性物質のフィルムで被膜してもよい。 In particular, when the present invention is applied to tablets, it may be coated with a sugar coating such as sucrose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate or a film of a gastric or enteric substance.
以上、本発明の好適な実施形態について説明したが、本発明は、これらに限定されない。 Although the preferred embodiments of the present invention have been described above, the present invention is not limited thereto.
例えば、前述した実施形態では、食品等の用途（例えば、［組成物、成形体］の項で例示した用途）には、脂肪代謝改善剤とその他の成分を含む組成物または成形体を適用する場合について代表的に説明したが、本発明の脂肪代謝改善剤（バラ花弁抽出物やその精製物等）そのものを、その他の成分と混合等することなく、上記のような用途に用いてもよい。この場合、これらの用途に用いられるものの形態としては、例えば、［組成物、成形体］の項で例示したようなもの等が挙げられる。 For example, in the embodiment described above, the composition or the molded article containing the fat metabolism improving agent and the other components is applied to the use such as food (for example, the use illustrated in the section [Composition, molded body]) Although the case has been described representatively, the agent for improving metabolism of the present invention (such as rose petal extract and its purified product) itself may be used for the above-mentioned applications without mixing with other components. . In this case, as a form of what is used for these uses, what was illustrated by the term of a [composition, a molded object] etc. is mentioned, for example.
以下に具体的な実施例をあげて本発明をさらに詳しく説明するが、本発明は、以下の実施例のみに限定されるものではない。なお、以下の説明において、特に温度条件、湿度条件を示していない処理は、室温（２３℃）、相対湿度５０％において行ったものである。また、各種測定条件についても、特に温度条件、湿度条件を示していないものは、室温（２３℃）、相対湿度５０％における数値である。 Hereinafter, the present invention will be described in more detail by way of specific examples, but the present invention is not limited to the following examples. In addition, in the following description, the process which has not shown temperature conditions and humidity conditions especially is performed at room temperature (23 degreeC) and 50% of relative humidity. Moreover, also about various measurement conditions, the thing which has not shown temperature conditions and humidity conditions in particular is a numerical value in room temperature (23 degreeC) and 50% of a relative humidity.
［バラ花弁抽出物（脂肪代謝改善剤）の調製］
（実施例１）
まず、バラとしてロサ・センチフォリアを用意した。
[Preparation of rose petal extract (fat metabolism improving agent)]
Example 1
First, I prepared Rosa centoforia as a rose.
ロサ・センチフォリアに乾燥処理を施し、この乾燥したロサ・センチフォリアの花弁２０ｋｇに、３０体積％のエタノール水溶液３００Ｌを加えて攪拌抽出した。 Rosa Centifolia was subjected to drying treatment, and 300 L of a 30% by volume aqueous solution of ethanol was added to 20 kg of the dried petals of Rosa Centifolia to extract with stirring.
その後、ろ過により固形物を除去した後、得られた抽出液を減圧濃縮し、合成吸着剤を充填したカラムを用いたカラムクロマトグラフィーに供した。溶離液としては、７０体積％のエタノール水溶液を用いた。 Then, after removing a solid substance by filtration, the obtained extract was concentrated under reduced pressure, and subjected to column chromatography using a column packed with a synthetic adsorbent. As an eluent, 70% by volume ethanol aqueous solution was used.
得られた溶出液を減圧濃縮した後、凍結乾燥することにより、平均粒径４２０μｍの粉末状のバラ花弁抽出物（脂肪代謝改善剤）を得た。 The obtained eluate was concentrated under reduced pressure and then freeze-dried to obtain a powdered rose petal extract (fat metabolism improving agent) in the form of a powder with an average particle diameter of 420 μm.
［評価］
以下に示す評価では、ヒト肝癌由来細胞株であるＨｅｐＧ２細胞に、バラ花弁抽出物（脂肪代謝改善剤）を添加し、２４時間放置した際の、脂肪代謝関連遺伝子の各ｍＲＮＡレベルに与える影響を、Ｒｅａｌ−ｔｉｍｅ定量ＰＣＲ（ｐｏｌｙｍｅｒａｓｅ ｃｈａｉｎ ｒｅａｃｔｉｏｎ）法により検討した。
[Evaluation]
In the evaluation shown below, the rose petal extract (fat metabolism improving agent) is added to HepG2 cells, a human hepatoma-derived cell line, and left for 24 hours to affect the mRNA levels of fat metabolism related genes. , Real-time quantitative PCR (polymerase chain reaction) method was examined.
＜条件１＞
（１日目）
チャコールデキストラン処理した１０％ＦＢＳ（ウシ胎児血清）を含有する、フェノールレッドフリーＤＭＥＭ（Ｄｕｌｂｅｃｃｏ’ｓ Ｍｏｄｉｆｉｅｄ Ｅａｇｌｅ Ｍｅｄｉｕｍ）を培地として用いた。
<Condition 1>
(1st day)
Phenol red free DMEM (Dulbecco's Modified Eagle Medium) containing charcoal dextran-treated 10% FBS (fetal bovine serum) was used as a medium.
１１×１０５ｃｅｌｌｓ／ｗｅｌｌとなるように６ウェル（ｗｅｌｌ）プレートにＨｅｐＧ２細胞をまき、３７℃、５％のＣＯ２存在下で、２４時間培養した。 HepG2 cells were seeded on a 6-well plate at 11 × 10 5 cells / well and cultured for 24 hours at 37 ° C. in the presence of 5% CO 2 .
ＦＢＳとしては、ＧＥ Ｈｅｌｔｈｃａｒｅ社製、ＨｙＣｌｏｎｅ（登録商標）、ＳＨ３００６８−０３を用いた。また、フェノールレッドフリーＤＭＥＭとしては、ＭＰ Ｂｉｏｍｅｄｉｃａｌｓ社製、１６４２７５４を用いた。また、６ウェルプレートとしては、Ｃｏｒｎｉｎｇ社製、ＦＡＬＣＯＮ（登録商標）、Ｎｏ．３５３０４６を用いた。 As the FBS, HyClone (registered trademark) and SH30068-03 manufactured by GE Helthcare were used. As phenol red free DMEM, 1642754 manufactured by MP Biomedicals was used. Moreover, as a 6 well plate, the product made by Corning, FALCON (registered trademark), no. 353046 was used.
（２日目（２４時間後））
１０％ＦＢＳ含有、フェノールレッドフリーＤＭＥＭで培地交換し、２４時間培養した。
(Day 2 (24 hours later))
The medium was replaced with phenol red free DMEM containing 10% FBS and cultured for 24 hours.
（３日目（４８時間後））
培地を吸引除去し、ＨｅｐＧ２細胞を２．５ｍＬの血清フリーフェノールレッドフリーＤＭＥＭで洗浄した。
(3rd day (after 48 hours))
The medium was aspirated off and HepG2 cells were washed with 2.5 mL serum free phenol red free DMEM.
バラ花弁抽出物（脂肪代謝改善剤）を１．０μｇ／ｍＬでＨｅｐＧ２細胞に添加し、２４時間培養した。 Rose petal extract (fat metabolism improving agent) was added to HepG2 cells at 1.0 μg / mL and cultured for 24 hours.
＜条件２＞
バラ花弁抽出物（脂肪代謝改善剤）の添加量を２．５μｇ／ｍＬとした以外は、前記条件１と同様にして培養した。
<Condition 2>
The culture was carried out in the same manner as the condition 1 except that the addition amount of the rose petal extract (fat metabolism improving agent) was 2.5 μg / mL.
＜条件３＞
バラ花弁抽出物（脂肪代謝改善剤）の添加量を５．０μｇ／ｍＬとした以外は、前記条件１と同様にして培養した。
<Condition 3>
The culture was carried out in the same manner as the condition 1 except that the addition amount of the rose petal extract (fat metabolism improving agent) was 5.0 μg / mL.
＜コントロール＞
バラ花弁抽出物（脂肪代謝改善剤）を添加しなかった（０．０μｇ／ｍＬ）以外は、前記条件１と同様にして培養した。
<Control>
The culture was carried out in the same manner as Condition 1 except that rose petal extract (fat metabolism improving agent) was not added (0.0 μg / mL).
２４時間培養後、すべてのＨｅｐＧ２細胞からｔｏｔａｌ ＲＮＡを回収し、Ｒｅａｌ−ｔｉｍｅ ＰＣＲによってＨｅｐＧ２細胞中の脂肪代謝関連遺伝子、およびβ−ａｃｔｉｎのｍＲＮＡレベルを測定した。 After 24 hours of culture, total RNA was recovered from all HepG2 cells, and fat metabolism related genes in HepG2 cells and mRNA levels of β-actin were measured by Real-time PCR.
脂肪代謝関連遺伝子としては、標的遺伝子としてＬＤＬＲ遺伝子、ＡＣＣ１遺伝子、ＦＡＳ遺伝子、ＡＣＯＸ遺伝子、ＣＰＴ１ａ遺伝子、ＳＲＥＢＰ１ｃ遺伝子について、そのＲＮＡレベルを測定した。
また、β−ａｃｔｉｎ ｍＲＮＡレベルは、データ補正として用いた。
As fat metabolism related genes, RNA levels of LDLR gene, ACC1 gene, FAS gene, ACOX gene, CPT1a gene and SREBP1c gene as target genes were measured.
In addition, β-actin mRNA levels were used as data correction.
ＬＤＬの取り込みに関与するＬＤＬＲ遺伝子の発現がコントロールに比べて増加したときは、脂肪輸送を促進するものと判断することができる。 When the expression of the LDLR gene involved in the uptake of LDL is increased compared to the control, it can be judged to promote fat transport.
脂肪酸のβ酸化に関与するＣＰＴ１ａ遺伝子、ＡＣＯＸ遺伝子の発現がコントロールに比べて増加したときは、脂肪の分解を促進するものと判断することができる。 When the expression of the CPT1a gene involved in β-oxidation of fatty acid and the ACOX gene is increased as compared to the control, it can be judged to promote the degradation of fat.
脂肪酸の合成に関与するＡＣＣ１遺伝子、ＳＲＥＢＰ１ｃ遺伝子、ＦＡＳ遺伝子の発現がコントロールに比べて減少したときは、脂肪の蓄積を抑制するものと判断することができる。 When the expression of the ACC1 gene, the SREBP1c gene, and the FAS gene involved in fatty acid synthesis is reduced as compared to the control, it can be judged that the accumulation of fat is suppressed.
Ｒｅａｌ−ｔｉｍｅ ＰＣＲで用いた、標的遺伝子の逆転写反応におけるプライマーの配列を表１に示す。実験結果の統計分析にはテューキーの検定（Ｔｕｋｅｙ’ｓ ｔｅｓｔ）を用いた。 The sequences of the primers in the reverse transcription reaction of the target gene used in Real-time PCR are shown in Table 1. For statistical analysis of the experimental results, Tukey's test was used.
ＨｅｐＧ２細胞にバラ花弁抽出物（脂肪代謝改善剤）を各種濃度で添加した場合の、ＬＤＬＲ遺伝子に対する影響を表２および図１に、ＡＣＣ１遺伝子に対する影響を表３および図２に、ＦＡＳ遺伝子に対する影響を表４および図３に、ＳＲＥＢＰ１ｃ遺伝子に対する影響を表５および図４に、ＡＣＯＸ遺伝子に対する影響を表６および図５に、ＣＰＴ１ａ遺伝子に対する影響を表７および図６に、それぞれ示す。 Table 2 and Figure 1 show the effect on the LDLR gene and Figure 3 and Figure 2 the effect on the FAS gene in HepG2 cells when rose petal extract (fat metabolism improving agent) is added at various concentrations. The effects on the SREBP1c gene are shown in Table 4 and FIG. 3, the effects on the ACOX gene are shown in Table 6 and FIG. 5, and the effects on the CPT1a gene are shown in Table 7 and FIG. 6, respectively.
なお、表２〜表７および図１〜図６において、「％ ｏｆ Ｃｏｎｔｒｏｌ」は、コントロールに対する各遺伝子発現量の変化割合を示す。 In Tables 2 to 7 and FIGS. 1 to 6, “% of Control” indicates the rate of change in the amount of expression of each gene relative to the control.
表２〜表７および図１〜図６から明らかなように、条件１〜条件３のいずれにおいても、本発明の脂肪代謝改善剤（バラ花弁抽出物）では、ＬＤＬの取り込みに関与するＬＤＬＲ遺伝子の発現がコントロールに比べて増加する傾向が認められ、脂肪酸のβ酸化に関与するＣＰＴ１ａ遺伝子、ＡＣＯＸ遺伝子の発現がコントロールに比べて増加する傾向が認められ、脂肪酸の合成に関与するＡＣＣ１遺伝子、ＳＲＥＢＰ１ｃ遺伝子、ＦＡＳ遺伝子の発現がコントロールに比べて減少する傾向が認められた。 As is clear from Tables 2 to 7 and FIGS. 1 to 6, in any of the conditions 1 to 3, in the fat metabolism improving agent (rose petal extract) of the present invention, the LDLR gene involved in the uptake of LDL The expression of CPT1a gene, which is involved in β-oxidation of fatty acid, and the expression of ACOX gene, which are involved in fatty acid β-oxidation, tend to be increased as compared to control, and the ACC1 gene, which is involved in fatty acid synthesis, SREBP1c The expression of the gene and FAS gene tended to decrease as compared to the control.
特に、ＬＤＬＲ遺伝子の発現については、条件１〜条件３のいずれにおいても有意に増加しており、ＡＣＣ１遺伝子の発現については、条件２において有意に増加しており、ＳＲＥＢＰ１ｃ遺伝子の発現については、条件２および条件３において有意に減少しており、ＡＣＯＸ遺伝子の発現については、条件１〜条件３のいずれにおいても有意に増加しており、ＣＰＴ１ａ遺伝子の発現については、条件２および条件３において有意に増加していた。 In particular, the expression of the LDLR gene is significantly increased under any of the conditions 1 to 3, and the expression of the ACC1 gene is significantly increased under the condition 2, and the condition for the expression of the SREBP1c is The expression of ACOX gene is significantly decreased in any of conditions 1 to 3, and the expression of CPT1a gene is significantly reduced in conditions 2 and 3. It was increasing.
このように、ヒト肝癌由来細胞株であるＨｅｐＧ２細胞に、バラ花弁抽出物（脂肪代謝改善剤）を投与することにより、非添加の場合（コントロール）に比べて、ＬＤＬの取り込みに関与するＬＤＬ受容体遺伝子、脂肪酸のβ酸化に関与するＣＰＴ１ａ遺伝子、ＡＣＯＸ遺伝子の発現が増加しており、バラ花弁抽出物（脂肪代謝改善剤）は、ＬＤＬの取り込みを促進し、さらに脂肪酸のβ酸化を促進するものと判断することができる。 Thus, administration of a rose petal extract (fat metabolism improving agent) to HepG2 cells, a human hepatoma-derived cell line, results in LDL acceptance related to LDL uptake compared to that in the absence (control). The expression of somatic genes, CPT1a gene involved in β-oxidation of fatty acid, and ACOX gene is increased, and rose petal extract (fat metabolism improving agent) promotes LDL uptake and further promotes β-oxidation of fatty acid It can be judged as a thing.
また、ＨｅｐＧ２細胞に、バラ花弁抽出物（脂肪代謝改善剤）を投与することにより、非添加の場合（コントロール）に比べて、脂肪酸の合成に関与するＡＣＣ１遺伝子、ＳＲＥＢＰ１ｃ遺伝子の発現が減少しており、バラ花弁抽出物（脂肪代謝改善剤）は、脂肪酸の合成を抑制するものと判断することができる。 In addition, administration of a rose petal extract (fat metabolism improving agent) to HepG2 cells reduces the expression of ACC1 gene and SREBP1c gene involved in fatty acid synthesis, as compared with no addition (control). The rose petal extract (fat metabolism improving agent) can be judged to suppress the synthesis of fatty acids.
したがって、バラ花弁抽出物（脂肪代謝改善剤）は、動物に投与されることで、血漿中から肝細胞へのＬＤＬの取り込み（脂肪輸送）、および、肝細胞における脂肪酸のβ酸化（脂肪分解）を促進し、かつ、肝細胞における脂肪酸の合成（脂肪蓄積）を抑制するという、細胞レベルで総合的に脂肪代謝をより効果的に改善するものと判断することができる。 Therefore, rose petal extract (fat metabolism improving agent) is administered to an animal, LDL uptake from plasma into hepatocytes (lip transport), and beta oxidation of fatty acid in hepatocytes (lipolysis) It can be judged that it promotes fat metabolism in a more comprehensive manner at the cellular level by promoting H. pylori and suppressing fatty acid synthesis (fat accumulation) in hepatocytes.
また、バラとして、ロサ・センチフォリアの代わりにロサ・ガリカを用いた以外は、前記実施例１と同様にしてバラ花弁抽出物（脂肪代謝改善剤）を得、これについて前記と同様の評価を行ったところ、前記と同様の結果が得られた。 As a rose, a rose petal extract (fat metabolism improving agent) was obtained in the same manner as in Example 1 except that Rosa Garica was used in place of Rosa Centifolia, and the same evaluation as described above was carried out. As a result, the same result as described above was obtained.
また、抽出溶媒としての水とエタノールとの混合溶媒中におけるエタノールの含有率を５体積％以上８０体積％以下の範囲で種々変更し、水の含有率を２０体積％以上９５体積％以下の範囲で種々変更した以外は、前記と同様にしてバラ花弁抽出物（脂肪代謝改善剤）を得、これについて前記と同様の評価を行ったところ、前記と同様の結果が得られた。 In addition, the content of ethanol in the mixed solvent of water and ethanol as the extraction solvent is variously changed in the range of 5% by volume to 80% by volume, and the content of water is in the range of 20% by volume to 95% by volume The rose petal extract (fat metabolism improving agent) was obtained in the same manner as described above, except that various changes were made. The same evaluation as described above was performed on this, and the same results as described above were obtained.
また、溶離液としての水とエタノールとの混合溶媒中におけるエタノールの含有率を２０体積％以上９５体積％以下の範囲で種々変更し、水の含有率を５体積％以上８０体積％以下の範囲で種々変更した以外は、前記と同様にしてバラ花弁抽出物（脂肪代謝改善剤）を得、これについて前記と同様の評価を行ったところ、前記と同様の結果が得られた。 In addition, the content of ethanol in the mixed solvent of water and ethanol as the eluent is variously changed in the range of 20% by volume to 95% by volume, and the content of water is in the range of 5% by volume to 80% by volume The rose petal extract (fat metabolism improving agent) was obtained in the same manner as described above, except that various changes were made. The same evaluation as described above was performed on this, and the same results as described above were obtained.
また、前記のようにして得られたバラ花弁抽出物（脂肪代謝改善剤）：１００質量部に対して、粉末状の澱粉：３９５質量部、微粒二酸化ケイ素：５質量部を混合して、食品（組成物）としての粉末混合品を得た。
また、当該組成物を圧縮成形して、ブロック状の食品（成形体）を得た。
In addition, 395 parts by mass of powdered starch and 5 parts by mass of fine particle silicon dioxide are mixed with 100 parts by mass of the rose petal extract (fat metabolism improving agent) obtained as described above, A powder mixture as (composition) was obtained.
In addition, the composition was compression-molded to obtain a block-like food (molded product).
これらの食品（粉末状の組成物およびブロック状の成形体）をボランティアの被験者に食してもらったところ、バラの香気が感じられる一方で、苦み、渋み、えぐみ等の不快な味覚は感じられず、全体として優れた風味が得られた。 When these food products (powdery composition and block-like molded product) were eaten by a volunteer subject, while the scent of roses was felt, the unpleasant taste such as bitterness, astringency, and bitter melon was felt. In addition, excellent flavor was obtained as a whole.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017238375A JP7024965B2 (en) | 2017-12-13 | 2017-12-13 | Method for Producing LDLR Gene Expression Promoting Agent in HepG2 Cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017238375A JP7024965B2 (en) | 2017-12-13 | 2017-12-13 | Method for Producing LDLR Gene Expression Promoting Agent in HepG2 Cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019104705A true JP2019104705A (en) | 2019-06-27 |
| JP7024965B2 JP7024965B2 (en) | 2022-02-24 |
Family
ID=67060957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017238375A Active JP7024965B2 (en) | 2017-12-13 | 2017-12-13 | Method for Producing LDLR Gene Expression Promoting Agent in HepG2 Cells |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7024965B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102172316B1 (en) * | 2020-02-05 | 2020-10-30 | 대한켐텍 주식회사 | A composition comprising rose flower extract for reducing body fat and a health functional food comprising the composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004043308A (en) * | 2002-05-22 | 2004-02-12 | Jun Yabuki | Therapeutic agent for atopic dermatitis comprising component extracted from rose petal as active ingredient |
| JP2005281262A (en) * | 2004-03-30 | 2005-10-13 | Toyo Hakko:Kk | Melanogenesis inhibitor and cosmetic material, cosmetic, food and drink additive and bath agent containing the melanogenesis inhibitor |
| JP2010070541A (en) * | 2008-08-22 | 2010-04-02 | Kao Corp | Tg synthesis inhibitor |
-
2017
- 2017-12-13 JP JP2017238375A patent/JP7024965B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004043308A (en) * | 2002-05-22 | 2004-02-12 | Jun Yabuki | Therapeutic agent for atopic dermatitis comprising component extracted from rose petal as active ingredient |
| JP2005281262A (en) * | 2004-03-30 | 2005-10-13 | Toyo Hakko:Kk | Melanogenesis inhibitor and cosmetic material, cosmetic, food and drink additive and bath agent containing the melanogenesis inhibitor |
| JP2010070541A (en) * | 2008-08-22 | 2010-04-02 | Kao Corp | Tg synthesis inhibitor |
Non-Patent Citations (1)
| Title |
|---|
| JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 57, JPN6021040007, 2009, pages 1786 - 1792, ISSN: 0004648887 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102172316B1 (en) * | 2020-02-05 | 2020-10-30 | 대한켐텍 주식회사 | A composition comprising rose flower extract for reducing body fat and a health functional food comprising the composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7024965B2 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5361820B2 (en) | Glutathione enhancing composition | |
| KR101651833B1 (en) | Composition for preventing hair loss or promoting hair growth comprising extract of citrus preicarp | |
| WO2012099449A2 (en) | Novel use of flavone-based compound | |
| KR101787531B1 (en) | Composition for preventing hair loss comprising extracts of crude drug complex | |
| KR20210002005A (en) | Composition comprising extract of buckwheat sprout for strengthening hair root, activating hair growth or preventing alopecia | |
| JP2023155452A (en) | Cell activator, melanin production inhibitor, and whitening agent | |
| TW201004688A (en) | Process for preparing a eucalyptus extract | |
| JP2023027253A (en) | Novel ellagitannin and agent for oral application | |
| WO2014034802A1 (en) | Transglutaminase activator | |
| JP2009269889A (en) | Glutathione production promoter, agent for preventing or treating disease caused by deficiency of glutathione, and food and drink | |
| JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
| KR102409079B1 (en) | Pharmaceutical composition for prevention or treatment of obesity comprising the extracts of Schizandra chinensis as active ingredient | |
| JP2019104705A (en) | Fat metabolism improver, method for producing fat metabolism improver, and composition and molding | |
| WO2010084661A1 (en) | Composition, food, food material, pharmaceutical preparation, cosmetic and commodity each containing isothiocyanate compound | |
| JP6647292B2 (en) | Composition for preventing hair loss or promoting hair growth comprising Scutellaria alpina extract | |
| JP2010150177A (en) | Fibroblast growth factor-7 (fgf-7) production promoter, insulin-like growth factor-1 (igf-1) production promoter, and hepatocyte growth factor (hgf) production promoter | |
| JP6338107B2 (en) | Skin barrier function improving agent, intercellular adhesion structure formation promoter, tight junction formation promoter, and TRPV4 gene expression enhancer | |
| JP6034107B2 (en) | Differentiation promoter from stem cells to brown adipocytes | |
| KR102486633B1 (en) | Lipid accumulation inhibitory or anti-obesity composition comprising ergosterol peroxide as an active ingredient | |
| KR101200716B1 (en) | Flavonoids inclusion complex derived from citron seed, a preparation method thereof, and uses thereof | |
| JP6386053B2 (en) | Hair growth or hair growth promoting composition containing 21-O-angeloyl theasapogenol E3 | |
| JP2013203730A (en) | Trichogenous agent | |
| JP5419258B2 (en) | Cosmetics | |
| JP5312063B2 (en) | FGF-7 production promoter, VEGF production promoter, IGF-1 production promoter, HGF production promoter, BMP-2 production promoter, FGF-18 production promoter, and type 2 testosterone 5α-reductase production inhibitor | |
| KR102443334B1 (en) | Composition with Anti-Inflammation, Skin Moisturizing, Pruritis Improving, and Skin Regeneration Property Comprising Complex Extract of Hibiscus Syriacus as Active Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180302 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20200917 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201026 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20201210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211012 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20211025 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211112 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220114 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220125 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220202 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7024965 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |